Abstract
Lymphatic filariasis (LF) is an infectious neglected tropical disease caused by a mosquito-borne nematode and is a major cause of disability. In 2022, it was estimated that 51 million people were infected with LF. In Kenya filariasis is endemic along the entire coastal strip. The main vectors are Anopheles funestus and Anopheles gambiae in rural areas and Culex quinquefaciatus mosquitoes in urban areas.
In 2022, mosquitoes were collected from Kilifi, Kwale and Taita-Taveta counties which are located within the LF endemic region in Kenya. Subsequently, genomic Deoxyribonucleic acid (DNA) was then extracted from these mosquitoes for speciation and analysis of W. bancrofti infection rates. The impact of socio-demographic and household attributes on infection rates were assessed using generalized estimating equations.
A total of 18,121 mosquitoes belonging to Culex (n = 11,414) and Anopheles (n = 6,707) genera were collected. Morphological identification revealed that Anopheline mosquito were dominated by An. funestus (n = 3,045) and An. gambiae (n = 2,873). Wuchereria bancrofti infection rates were highest in Kilifi (35.4%; 95% CI 28%-43.3%, n = 57/161) and lowest in Taita Taveta (5.3%; 95% CI 3.3%-8.0%, n = 22/412). The major vectors incriminated are An. rivulorum, An. funestus sensu stricto and An. arabiensis. The risk of W. bancrofti infection was significantly higher in An. funestus complex (OR = 18.0; 95% CI 1.80-180; p = 0.014) compared to An. gambiae (OR = 1.54; 95% CI 0.16-15.10; p = 0.7). Additionally, higher risk was observed in outdoor resting mosquitoes (OR = 1.72; 95% CI 1.06-2.78; p = 0.027) and in homesteads that owned livestock (OR = 2.05; 95% CI 1.11-3.73; p = 0.021). Bednet (OR = 0.39; 95% CI 0.12-1.32; p = 0.13) and poultry ownership (OR = 0.52; 95% CI 0.30-0.89, p = 0.018) seems to provide protection.
Anopheles funestus complex emerged as the primary vectors of lymphatic filariasis along the Kenyan coast. These findings also highlight that a significant portion of disease transmission potentially occurs outdoors. Therefore, control measures targeting outdoor resting mosquitoes such as zooprophylaxis, larval source management and attractive sugar baits may have potential for LF transmission reduction.
Author summary Lymphatic filariasis (LF) in the African continent is mainly caused by a mosquito-borne nematode: Wuchereria bancrofti. In urban areas transmission is mainly by Culex quinquefaciatus whereas in rural areas it is dominated by Anopheles funestus and Anopheles gambiae mosquitoes. We investigated the vectorial systems for LF in rural coastal Kenya and factors associated with the risk of diseases transmission in the region. We identified An. funestus sensu lato sibling species An. rivulorum and An. funestus sensu stricto as the dominant vectors of lymphatic filariasis along the Kenyan coast. We also show that a higher proportion of transmission is likely to take place outdoors necessitating the implementation of vector control strategies that target exophilic mosquitoes such as zooprophylaxis and larval source management. Factors associated with transmission of LF include ownership of livestock and houses made of natural materials such as thatched roof and mud walls. Bednet and poulty ownership were associated with protection. We also highlight the importance of molecular xenomonitoring in the surveillance of lymphatic filariasis, because of its’ non-invasive nature and potential for incriminating new vectors of lymphatic filariasis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the KEMRI Scientific and Ethics Review Unit (SERU) with the protocol number: KEMRI/SERU/CGMR-C/024/3148. Verbal informed consent was obtained from the household heads before metadata and mosquito collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Most of the dataset used for analysis is available in the manuscript. We withheld the geo-data which may predispose individual homesteads to a high risk of identifiability. However, they are under the custodianship of the KEMRI-Wellcome Trust Data Governance Committee and are accessible upon request addressed to that committee.
